Westfield Capital Management CO LP Cyma Bay Therapeutics, Inc. Transaction History

Westfield Capital Management CO LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$12.63 - $24.47 $8.84 Million - $17.1 Million	700,056 New	700,056 $16.5 Million
Q2 2019 Aug 13, 2019	SELL	$6.05 - $13.66 $5.05 Million - $11.4 Million	-834,330 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$8.16 - $13.42 $1.97 Million - $3.25 Million	-241,885 Reduced 22.48%	834,330 $11.1 Million
Q4 2018 Feb 08, 2019	BUY	$6.54 - $11.74 $1.09 Million - $1.96 Million	166,835 Added 18.35%	1,076,215 $8.47 Million
Q3 2018 Nov 14, 2018	SELL	$10.88 - $14.52 $63,539 - $84,796	-5,840 Reduced 0.64%	909,380 $10.1 Million
Q2 2018 Aug 13, 2018	BUY	$10.66 - $14.38 $9.76 Million - $13.2 Million	915,220 New	915,220 $12.3 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Westfield Capital Management CO LP, based on Form 13F filings with the SEC.

Stay updated on Westfield Capital Management CO LP with notifications on news.